Incidence of Septic Shock in the ImmunoSep Clinical Trial

Overview

The ImmunoSep trial demonstrated improved organ dysfunction with biomarker-guided immunotherapy in sepsis but revealed a higher incidence of new-onset septic shock in the immunotherapy group compared to placebo. Although the increased septic shock events may be clinically relevant, the findings are exploratory and require cautious interpretation due to small event numbers and potential confounding factors.

Background

Sepsis is a heterogeneous syndrome with variable immune responses, prompting investigation into biomarker-guided immunotherapy targeting specific endotypes. The ImmunoSep trial evaluated precision immunotherapy using anakinra for macrophage activation–like syndrome and recombinant human interferon-γ for sepsis-induced immunoparalysis. The primary endpoint was improvement in organ dysfunction by day 9, with mortality at 28 days as a secondary outcome. Safety data revealed occurrences of new septic shock episodes after initial resolution, raising questions about treatment-related risks.

Data Highlights

Key Findings

• New-onset septic shock occurred in 22.1% of patients receiving immunotherapy versus 11.7% receiving placebo (crude OR 2.1, 95% CI 1.1–4.1).
• Within macrophage activation–like syndrome, 28.0% treated with anakinra developed septic shock compared to 13.0% on placebo.
• In sepsis-induced immunoparalysis, 20.8% treated with interferon-γ developed septic shock versus 11.5% on placebo.
• Events were adjudicated as unrelated or probably unrelated to study drugs, but the absolute risk difference (~10%) may be clinically meaningful.
• The small number of events limits statistical robustness; minor changes could alter risk estimates, especially within endotype subgroups.
• Mechanistic interpretation is complex due to distinct immunomodulatory approaches and incomplete understanding of cytokine effects during sepsis.

Clinical Implications

Clinicians should recognize that while biomarker-guided immunotherapy improves organ dysfunction, there may be an increased risk of secondary septic shock events, warranting careful monitoring. These findings highlight the need for cautious interpretation and further investigation into the safety profile and mechanistic effects of immunomodulatory treatments in sepsis. Understanding patient endotypes and temporal relationships between therapy and septic shock onset is essential for optimizing risk–benefit assessments.

Conclusion

The ImmunoSep trial supports precision immunotherapy for sepsis but signals a potential increase in new septic shock episodes that require further study. These exploratory safety findings underscore the complexity of immune modulation in sepsis and the importance of continued evaluation of treatment risks alongside benefits.

References

1. ImmunoSep Trial, JAMA 2024 -- Biomarker-guided Immunotherapy in Sepsis